Scientific Staff Profiles

This page allows you to read information about people engaged in research at CAMH. You can search for researchers using the name or keyword search engine below.

Dr. Jeffrey Meyer

PET Centre
Centre for Addiction and Mental Health
250 College Street
Toronto, Ontario M5T 1R8
(416) 535-8501
jeff_meyer@camh.net

Dr. Jeffrey Meyer is a Senior Scientist and head of the Neurochemical Imaging program, Mood and Anxiety Disorders program, at the CAMH PET Centre. Dr. Meyer is also an Associate Professor in the Department of Psychiatry at the University of Toronto .

Search again?

Areas of Research

Dr. Jeffrey Meyer's research focuses on understanding the neurochemical basis of depression and the neurochemical effects of antidepressant treatment. Through this work, Dr. Meyer developed a new leading monoamine theory of depression.

Dr. Meyer also conducted and published leading antidepressant occupancy studies for serotonin and dopamine transporters, 5-HT2A receptors and monoamine oxidase. This work established a therapeutic occupancy for selective serotonin reuptake inhibitors. His publications include 45 peer-reviewed papers, 50 per cent as first/senior author, with 12 top-level publications. He is published in journals such as the Archive of General Psychiatry and the American Journal of Psychiatry.

In the future, Dr. Meyer will extend the range of mood disorder research at CAMH by directing projects investigating postpartum depression, biological predictors of recurrence, and antidepressant occupancy for novel target sites.

Publications

Praschak-Rieder N, Kennedy J, Wilson AA, Hussey D, Boovariwala A, Willeit M, Ginovart N, Tharmalingam S, Masellis M, Houle S, Meyer JH. Novel 5-HTTLPR Allele Associates With Higher SerotoninTransporter Binding in Putamen: An [11C] DASB Positron Emission Tomography Study. Biological Psychiatry 2007; 62(4): 327-31.

Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, Young LT, Praschak-Rieder N, Wilson AA, Houle S. Elevated Brain Monoamine Oxidase-A: An Explanation for the Monoamine Imbalance of Major Depression. Archives of General Psychiatry 2006; 63(11): 1209-1216.
Meyer JH, McNeely H, Sagrati S, Boovariwala A, Martin K, Verhoeff NPLG, Wilson AA, Houle S. Striatal D₂Receptor Binding Potential and its Relationship to Motor Retardation in Major Depression. American Journal of Psychiatry 2006; 163(9):1594-602.

Praschak-Rieder N, Wilson AA, Hussey DH, Carella A, Wei C, Ginovart N, Schwarz MJ, Zach J, Houle S, Meyer JH. Effects of Tryptophan Depletion Upon the Serotonin Transporter in Healthy Humans. Biological Psychiatry 2005; 58(10):825-30.

Meyer JH, Houle S, Sagrati S, Carella A, Hussey D, Ginovart N, Goulding V, Kennedy JL, Wilson AA. The Serotonin Transporter and its Relationship to Dysfunctional AttitudesDuring Major Depressive Episodes. Archives of General Psychiatry 2004; 61(12): 1271-1279.

Praschak-Rieder N,Hussey D, Wilson AA, Carella A, Lee M, Dunn E, Willeit M, Bagby M, Houle S, Meyer JH. Tryptophan Depletion and Serotonin Loss in SSRI Treated Depression: A [¹⁸F] MPPF PET Study Biol Psychiatry 2004; 56(8): 587-91.

Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S. Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [¹¹C] DASB Positron Emission Tomography Study. American Journal of Psychiatry 2004; 161(5): 826-35.

Meyer JH, McMain S, Kennedy SH, Korman L, Brown GM, DaSilva JN, Wilson AA, Blak T, Eynan-Harvey R, Goulding VS, Houle S, Links P. Dysfunctional Attitudes and Serotonin2 Receptors During Depression and Self Harm. American Journal of Psychiatry 2003; 160(1):90-9.

Meyer JH, Goulding V, Wilson AA, Christensen BK, Hussey D, Houle S. Bupropion Occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology 2002; 163(1):102-5.

Meyer JH, Krüeger S, Wilson AA, Christensen BK, Goulding V, Schaffer A, Houle S, Hussey D, Kennedy S. Lower Dopamine Transporters Binding Potential in Striatum During Depression. Neuroreport 2001; 12(18): 4121-4125.

Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, Houle S. Occupancy of Serotonin Transporters by Paroxetine and Citalopram During Treatment of Depression: A [11C] DASB PET Imaging Study. American Journal of Psychiatry 2001; 158(11):1843-9.
Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, Wilson AA, Rafi-Tari S, Mayberg HS, Kennedy SH. The Effect of Paroxetine Upon 5-HT2A Receptors in Depression An [¹⁸F] Setoperone PET Imaging Study. American Journal of Psychiatry 2001; 158:78-85.

Meyer JH, Ichise M. Modeling of Receptor Ligand Data in PET and SPECT Imaging: a review of major approaches. Journal of Neuroimaging 2001; 11: 30-39.

Meyer JH, Kapur S, Houle S, DaSilva J, Owczarek B, Brown GM, Wilson AA, Kennedy SH. Prefrontal Cortex 5-HT₂ Receptors in Depression: [¹⁸F] Setoperone PET Imaging. American Journal of Psychiatry 1999; 156(7): 1029-1034.
Meyer JH, Cho R, Kennedy SH, Kapur S. The Effects of Single Dose Nefazodone and Paroxetine Upon 5-HT₂ Binding Potential in Humans Using [¹⁸F] Setoperone PET. Psychopharmacology 1999; 144: 279-281.

Meyer JH, Gunn RN, Myers R, Grasby PM. Assessment of Spatial Normalisation of PET Ligand Images Using Ligand Specific Templates. Neuroimage 1999; 9: 545-553.

Meyer JH, Kennedy SH, Brown GM. No Effect of Depression on [¹⁵O] H₂O PET Response to Intravenous d-Fenfluramine.American Journal of Psychiatry 1998; 155: 1241-1246.

Search again?

ID#29600 -SP
Content updated: April 30, 2007 11:19 AM